Director/PDMR Shareholding

RNS Number : 6210A

MGC Pharmaceuticals Limited

03 February 2022

 

MGC Pharmaceuticals Ltd.

PDMR Notification

03 February 2022

ASX, LSE: MXC

MGC Pharmaceuticals Ltd ('MGC Pharma' or 'the Company') wishes to advise that the following Person Discharging Managerial Responsibilities (PDMR) has dealt with shares in MGC Pharma, and this notification is made in accordance with UK Market Abuse Regulations.

The shares the subject of this notice were sold by a PDMR who in May 2021, sold her business, MediCaNL Inc, a pharmaceutical research company, to MGC Pharma, and which is now a wholly owned subsidiary of the Company.  Details of the MedicaNL transaction are detailed in MGC Pharma's ASX announcement on 22 April 2021, a copy of which can be found at the following URL:

https://www.asx.com.au/asxpdf/20210422/pdf/44vrj4zvy8ztjr.pdf  

The PDMR subsequently sold a portion of the vendor consideration shares received under the acquisition terms, in order to satisfy personal capital gains tax liabilities which arose from the PDMR's sale of MediCaNL Inc to MGC Pharma.

1	Details of the person discharging managerial responsibilities/person closely associated
(a)	Name		Nadya Lisovoder
2	Reason for the notification
(a)	Position		Leading CRO
(b)	Initial notification/amendment		Initial
(c)	If amendment: reason		n/a
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
	Full name of entity		MGC Pharmaceuticals Limited
	Legal Entity Identifier Code		213800HRE3FQJ6RK4H10
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; (iv) each place where transactions have been conducted
(a)	Description of the financial instrument, type of instrument		Fully Paid Ordinary Shares
(b)	Identification Code (ISIN)		AU000000MXC6
(c)	Nature of transaction		Disposal of Shares
(d)	Currency	Price		Volume	Total
	1.  AUD 2.  AUD 3.  AUD	$0.048 $0.050 $0.058		934,547 7,717,996 13,442,365	$44,858 $387,443 $779,657
	Aggregated information
	AUD	$0.055		22,094,908	$1,211,959
(e)	Date of transaction		1.  2021-09-01 2.  2021-09-03 3.  2021-09-30
(f)	Place of transaction		Australian Stock Exchange

--Ends--

Authorised for release by the Executive Chair, for further information please contact:

MGC Pharmaceuticals Ltd Roby Zomer CEO & Managing Director [phone] [e-mail]	MGC Pharmaceuticals Ltd David Lim Company Secretary [phone] [e-mail]
UK Broker - Turner Pope Andy Thacker [phone] [e-mail]	UK PR Advisors - Tavistock Charles Vivian / Tim Pearson [phone] [e-mail]

 

END

 

 

DSHBGGDDIDGDGDX